Antibodies Elicited by the 2025–2026 Influenza Vaccine
NEJM Evidence · 24.03.2026 · 5 (4)
DOI: 10.1056/evidpha2600007 ↗Kurz gefasst
Fachartikel in der Zeitschrift NEJM Evidence, erschienen am 24.03.2026. Verfasst von Jiaojiao Liu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Hauptthemen laut MEDLINE: Antibodies, Viral, Influenza A Virus, H3N2 Subtype, Influenza Vaccines, Influenza, Human. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 4 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
- Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Zitieren
APA
Liu, J., Li, S. H., Ye, N., Griffiths, T., Drapeau, E. M., Atkinson, R. K., Collman, R. G., & Hensley, S. E. (2026). Antibodies Elicited by the 2025–2026 Influenza Vaccine. NEJM Evidence, 5(4). https://doi.org/10.1056/evidpha2600007
Vancouver
Liu J, Li SH, Ye N, Griffiths T, Drapeau EM, Atkinson RK, et al. Antibodies Elicited by the 2025–2026 Influenza Vaccine. NEJM Evidence. 2026;5(4). doi:10.1056/evidpha2600007
BibTeX
@article{Liu2026,
author = {Liu, Jiaojiao and Li, Shuk Hang and Ye, Naiqing and Griffiths, Tachianna and Drapeau, Elizabeth M and Atkinson, Reilly K and Collman, Ronald G and Hensley, Scott E},
title = {Antibodies Elicited by the 2025–2026 Influenza Vaccine},
journal = {NEJM Evidence},
year = {2026},
volume = {5},
number = {4},
doi = {10.1056/evidpha2600007}
}
EUVIMED